David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology, joins Theolytics Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer Oxford UK, December 17, 2024. Theolytics, a clinical-stage... read full story
"The Theolytics Board is delighted that David has joined us in this role and is confident in his ability to build on the key milestones achieved by the founding team."